Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568203 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01568203 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 50 participants.
The verdict
NCT01568203, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of AMG 579 following a single oral dose administration in healthy subjects (Part A) and in patients with schizophrenia or stable schizoaffective disorder (Part B). The study in healthy subjects (Part A) concluded, and following a protocol amendment, enrolled only patients with schizophrenia or stable schizoaffective disorder (Part B).
Interventions
- DRUG Placebo
- DRUG AMG 579
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01568203
The ClinicalTrials.gov registry entry for NCT01568203 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01568203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01568203 about?
NCT01568203 is a clinical study titled "First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia". The purpose of this study is to assess the safety and tolerability of AMG 579 following a single oral dose administration in healthy subjects (Part A) and in patients with schizophrenia or stable schizoaffective disorder (Part B). The study in healthy subjects (Part A) concluded, and following a pro...
What is the current status of trial NCT01568203?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01568203?
The interventions under investigation include: Placebo (DRUG), AMG 579 (DRUG).
Who is sponsoring clinical trial NCT01568203?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.